What Indocollyre Treats: Main Uses and Benefits

Indocollyre 0.1% eye drops' primary therapeutic role is in supporting the management of symptoms related to inflammatory or irritative states and related symptoms related to physical discomfort in the anterior segment of the eye, particularly in contexts following surgery. This medication is used in conditions characterized by periods of heightened symptoms, specifically applied in clinical settings that involve acute or unstable symptom patterns often used during ophthalmic procedures, as well as for supportive relief when symptoms of inflammatory or irritative states may intensify temporarily following cataract surgery or other anterior chamber eye surgery.

This medication is commonly used to help with symptom clusters that may become intense or disruptive, such as swelling and pain, and is applied in scenarios where additional management of discomfort is required. It may also assist with symptomatic relief that helps patients cope more steadily with ocular pain following certain laser procedures, like photorefractive keratectomy. This supportive approach contributes to easing the overall symptom load and supports general well-being during symptomatic phases associated with these ophthalmic procedures.

---

Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

1. Indocollyre 0.1% Eye Drops Overview

This section summarizes official regulatory information defining which patient groups are eligible or excluded from using Indocollyre (Indometacin eye drops).

---

Contraindications (Must Not Use)

Indocollyre is strictly contraindicated for patients with:

• Known Hypersensitivity: Allergy to Indometacin or any other non-steroidal anti-inflammatory drug (NSAID), including aspirin (acetylsalicylic acid).
• Asthma: A history of asthma attacks or allergic reactions (urticaria) caused by aspirin or other NSAIDs.
• Pregnancy (Third Trimester): Use is prohibited from the sixth month of pregnancy onwards (starting at 30 weeks' gestation) due to risk to the fetus.

---

Use Limitations and Special Populations

Population/Condition	Eligibility Status (Regulatory)
Children/Pediatrics	Safety and efficacy has not been established.
Breastfeeding Women	Not recommended or should be avoided as a precautionary measure.
Pregnancy (Trimesters 1 & 2)	Use only if the potential benefit justifies the potential risk.
Patients with Bleeding Tendency	Use with special caution as NSAIDs may increase bleeding risk during surgery.
Contact Lens Wearers	Contact lenses should not be worn during treatment.

---

This medication is typically intended for adult use without the noted contraindications or restrictions. Official regulatory labeling requires specific precautions for conditions such as corneal surface damage.

Interactions with other medicines and products

The official interaction profile for Indocollyre (Indometacin ophthalmic solution) is primarily based on the drug's classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and specific constraints for topical administration. Regulatory documents use terms like Inadvisable Combinations and Combinations to Take into Account to define necessary constraints.

Interaction Scope and Restrictions

Property	Description
Timing-based rule	Co-administration with a different active eye-drop preparation requires a minimum 15-minute separation between instillations.
Inadvisable Combinations	Co-administration with Oral Anticoagulants or Injectable Heparin is formally noted as inadvisable due to an increased risk of bleeding.
Exposure effects	Co-administration with Lithium is inadvisable due to a risk of increased Lithium blood levels, resulting from reduced clearance.
Pharmacodynamic effects	Co-administration with Antihypertensive Agents (e.g., ACE Inhibitors, Diuretics) may result in a reduced antihypertensive effect.
Class restriction	The drug is contraindicated in patients with a history of asthma attacks or hypersensitivity caused by aspirin or other NSAIDs.

Connection to the overall interaction profile

The product’s official interaction profile is defined by mandatory timing rules for its ophthalmic formulation and specific regulatory statements regarding the inadvisable co-administration of agents like anticoagulants, other NSAIDs, and Lithium. This structure addresses both the drug class pharmacology and the required procedural constraints for ophthalmic use.

Nonselective Inhibition of Cyclooxygenase Enzymes ( COX-1 and COX-2)

The drug's primary action involves acting as a nonselective inhibitor of the COX enzymes, which are the biological targets that catalyze the conversion of arachidonic acid into prostaglandins and other pro-inflammatory mediators. This mechanism fundamentally suppresses the Prostaglandin Synthesis Pathway, directly suppresses the molecular synthesis of signals that induce local physiological responses such as vasodilation and increased capillary permeability.

---

Modulation of Local Ocular Barrier and Nociception

By reducing the concentration of prostaglandins in the ocular tissue, the drug initiates a cascading effect that influences both the BAB and peripheral nerve endings. This mechanism contributes to the maintenance of the Blood-Aqueous Barrier integrity, restricting the influx of fluid and proteins, and decreases the sensitization of nociceptive (pain-sensing) nerves, thus modulating afferent physiological signaling.

---

Secondary Non-Eicosanoid Mechanisms

Indometacin also engages mechanisms independent of COX inhibition, including a unique action that results in direct vasoconstriction of ocular blood vessels and an interaction with the CRTH2 receptor. These secondary mechanisms contribute to a more localized modulation of the inflammatory environment and microvascular tone within the anterior segment of the eye.

The administration of Indocollyre 0.1% eye drops is defined by specific, high-frequency schedules applied strictly via topical ocular instillation. The solution is intended for use in the peri-operative setting of ophthalmic procedures. Use is structured around specific adult regimens, with dosing recommendations may vary across different regions.

Official Administration Schedules

Purpose	Regimen	Frequency and Duration
Inhibition of Miosis	1 drop	Every 30 minutes for up to 2 hours preceding the operation.
Prevention of Post-Operative Inflammation	1 drop	4 to 6 times daily beginning the day before surgery, continuing post-operatively (e.g., up to one month).

---

Procedural and Contextual Instructions

The primary route of use is localized, requiring no preparation or dilution of the sterile solution. The standard technique involves gently pulling down the lower eyelid and looking up while instilling a single drop.

Co-Administration: If a patient is receiving treatment with other eye-drop preparations, it is required that the two solutions be administered with a minimum separation of 15 minutes.

Population Specifics: The safety and efficacy of Indocollyre have not been established for use in children.

Handling Constraints: Practical administration constraints include the advisability of not wearing contact lenses during the course of treatment, as well as the instruction to avoid touching the eye with the bottle tip to maintain the sterility of the solution.

Indocollyre: Recent Clinical Evidence

Evidence for use in reducing inflammation after eye surgery

Research has primarily explored the use of Indocollyre in patients immediately following eye surgery, such as cataract surgery. These clinical trials was studied for a short period to look at outcomes linked to inflammatory or irritative states, like swelling and irritation in the eye, and outcomes related to physical discomfort. The findings indicate that research noted patterns in measures of inflammation and patient-reported discomfort during the weeks immediately after surgery. These trials contribute to the broader evidence landscape by providing context on how the eye may respond when facing the temporary physiological imbalance caused by surgery.

Evidence for use in managing non-surgical eye pain and inflammation

This part will review the studies exploring Indocollyre in contexts related to pain and swelling associated with various non-surgical eye conditions, which may include specific types of superficial ocular inflammation or pain following accidental corneal injury. The data show patterns related to how outcomes related to physical discomfort changed in patients during periods of increased symptom activity. For instance, some research describes how patient-reported discomfort evolved in the observed populations during the first few days after an injury.

---

Long-term studies and follow-up

Currently, there is limited information for long-term outcomes that look past the initial follow-up periods of a few weeks or months. Evidence about the patterns observed over extended periods—meaning whether the patterns observed may last long after the drops are stopped—is an area where more research is needed. The evidence highlights what is known — and what is still uncertain regarding outcomes over time.

---

What is still uncertain about Indocollyre

Despite available research, a major area of uncertainty is the lack of extensive long-term data; long-term effects are not fully established. Furthermore, comparative evidence is lacking, and these specific comparisons have not been fully studied. In some scenarios, the findings were mixed regarding certain patient-reported outcomes describing perceived discomfort. Overall, the available research describes patterns observed in the studies but does not determine whether an individual will respond similarly, underscoring the need for ongoing investigation.

Common questions about Indocollyre (FAQ)

Q: What is Indocollyre and what is it used for?

Indocollyre is the brand name for indomethacin eye drops. It belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).

It is used to relieve pain and inflammation in the eye, often following cataract surgery or other types of eye surgery. It can also be used to prevent certain complications, like pupillary constriction (a small pupil) during surgery.

---

Q: How do I use Indocollyre eye drops?

• Wash your hands thoroughly before use.
• Tilt your head back slightly and pull down your lower eyelid to create a small pocket.
• Hold the dropper over the eye with the tip down.
• Look up and instill the prescribed number of drops into the pocket.
• Close your eye gently and press a finger to the inner corner of your eye (near the nose) for one to two minutes. This helps the medicine stay in the eye.
• Do not let the dropper tip touch your eye or any other surface to avoid contamination.
• If you are using other eye drops, wait at least five minutes between applying different products.
• Always follow the specific instructions given by your doctor or pharmacist.

---

Q: What are the common side effects of Indocollyre?

Like all medicines, Indocollyre can cause side effects, though not everyone gets them.

The most common side effects are usually related to the area of application and may include:

• A stinging or burning sensation in the eye immediately after use.
• Temporary blurred vision.
• Eye irritation or discomfort.
• Itching of the eye.

If you notice any severe side effects, or if the common side effects persist or worsen, you should contact your doctor immediately.

---

Q: Can I wear contact lenses while using Indocollyre?

No, it is generally not recommended to wear contact lenses while being treated with Indocollyre eye drops, especially soft contact lenses.

This is because the preservative in the eye drops (often benzalkonium chloride) can be absorbed by soft contact lenses, which may damage the lenses or irritate the eye.

If you wear contact lenses, you should remove them before applying Indocollyre and wait at least 15 minutes after using the drops before reinserting them. Your doctor will provide the best guidance based on your specific eye condition and the reason for treatment.

Indocollyre (indomethacin ophthalmic solution) should be stored according to the instructions on the original packaging to maintain its efficacy. Generally, this medication must be kept out of the reach of children, in a safe and secure location. Do not store the eye drops in a place with excess heat or moisture, such as a bathroom, as this can affect the quality of the solution.

After first opening the container, follow the specific instructions regarding the maximum period of use, which is typically a short duration like 15 days, after which any remaining medicine should be discarded. The safest and most recommended method for disposing of unused or expired Indocollyre is through a community drug take-back program or a medicine mail-back service. If these options are not available, you can dispose of the medicine in your household trash by mixing the liquid with an undesirable substance, such as used coffee grounds or cat litter, placing the mixture in a sealed bag or container, and then discarding it in the trash. Always remove or obscure all personal identifying information from the packaging before disposal.